Paving the Way for a Novel Therapeutic Approach to Combat HIV

为对抗艾滋病毒的新治疗方法铺平道路

基本信息

  • 批准号:
    8358310
  • 负责人:
  • 金额:
    $ 264万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-30 至 2017-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (Provided by the applicant) Abstract: Two strategies are currently in place to control the HIV pandemic: (1) anti-retroviral treatment reduces HIV-associated morbidity and mortality by controlling viral replication in infected subjects, thus also reducing the risk of viral dissemination; and (2) a comprehensive prevention package, including HIV vaccines, microbicides and pre-exposure prophylaxis regimens is being tested and aims at preventing new infections. Substantial effort has been invested in continuously improving these strategies, but there are several limitations to their further enhancement, many of which are related to HIV's vast mutational capacity. Instead of further refining current efforts that are confined by the limitations of these two strategies, we propose to introduce a third strategy. Our aim is to directly preserve the viability of uninfected CD4 T cells but not activated, infected cells, thus maintaining a functional immune system and limiting viral replication. HIV infection causes the loss of na¿ve CD4 T cells, which incapacitates the adaptive immune response and thus ultimately leads to AIDS, the inability to fight off infections and development of certain cancers. The vast majority of CD4 T cells die without actually being infected. We propose to rescue these na¿ve bystander CD4 T cells by targeting T cell metabolism. We present a strategy that aims to exploit the metabolic differences of uninfected, resting CD4 T cells and infected, activated CD4 T cells to selectively save the former but not the latter. This strategy is based on controlling the activity of pro-apoptotic BH3 family and tumor necrosis factor (TNF) superfamily members to control CD4 T cell viability. We propose to dissect how various metabolic signals are integrated in primary human CD4 T cells to regulate these apoptotic effector molecules using the recently established system of optogenetics. We propose that our strategy has merit to serve as a stand-alone approach or could be used in conjunction with both existing strategies to control the HIV pandemic. Public Health Relevance: HIV has caused the death of more than 25 million people. Despite efforts to limit mortality and further spreading of the virus there were still 2.6 million new infections and 1.8 million deaths in 2009. We propose a new strategy to combat this pandemic by manipulating T cell metabolism to prevent CD4 T cell loss and maintain a functional immune system with the goal of eliminating viral replication.
描述(由申请人提供)

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Martin Prlic其他文献

Martin Prlic的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Martin Prlic', 18)}}的其他基金

Single-Cell Analysis To Define Protective and Tolerizing Immune Cell Populations in the Human Placenta
单细胞分析确定人胎盘中的保护性和耐受性免疫细胞群
  • 批准号:
    9978484
  • 财政年份:
    2020
  • 资助金额:
    $ 264万
  • 项目类别:
Single-Cell Analysis To Define Protective and Tolerizing Immune Cell Populations in the Human Placenta
单细胞分析确定人胎盘中的保护性和耐受性免疫细胞群
  • 批准号:
    10594099
  • 财政年份:
    2020
  • 资助金额:
    $ 264万
  • 项目类别:
Single-Cell Analysis To Define Protective and Tolerizing Immune Cell Populations in the Human Placenta
单细胞分析确定人胎盘中的保护性和耐受性免疫细胞群
  • 批准号:
    10401230
  • 财政年份:
    2020
  • 资助金额:
    $ 264万
  • 项目类别:
Inflammation-driven T Cell Responses and their Dichotomous Effect on Host Immunity
炎症驱动的 T 细胞反应及其对宿主免疫的二分效应
  • 批准号:
    10593467
  • 财政年份:
    2016
  • 资助金额:
    $ 264万
  • 项目类别:
Inflammation-driven T Cell Responses and their Dichotomous Effect on Host Immunity
炎症驱动的 T 细胞反应及其对宿主免疫的二分效应
  • 批准号:
    10058804
  • 财政年份:
    2016
  • 资助金额:
    $ 264万
  • 项目类别:
Inflammation-driven T Cell Responses and their Dichotomous Effect on Host Immunity
炎症驱动的 T 细胞反应及其对宿主免疫的二分效应
  • 批准号:
    10682491
  • 财政年份:
    2016
  • 资助金额:
    $ 264万
  • 项目类别:
CD8 Tau cell contraction and memory formation
CD8 Tau细胞收缩和记忆形成
  • 批准号:
    7660600
  • 财政年份:
    2009
  • 资助金额:
    $ 264万
  • 项目类别:
CD8 Tau cell contraction and memory formation
CD8 Tau细胞收缩和记忆形成
  • 批准号:
    8282722
  • 财政年份:
    2009
  • 资助金额:
    $ 264万
  • 项目类别:
CD8 Tau cell contraction and memory formation
CD8 Tau细胞收缩和记忆形成
  • 批准号:
    8210398
  • 财政年份:
    2009
  • 资助金额:
    $ 264万
  • 项目类别:

相似海外基金

RESISTANCE OF HIV-1 TO ANTI-RETROVIRAL AGENTS
HIV-1 对抗逆转录病毒药物的耐药性
  • 批准号:
    3030975
  • 财政年份:
    1993
  • 资助金额:
    $ 264万
  • 项目类别:
POLYMERICS DELIVERY SYSTEMS FOR ANTI-RETROVIRAL AGENTS
抗逆转录病毒药物的聚合物递送系统
  • 批准号:
    3489187
  • 财政年份:
    1990
  • 资助金额:
    $ 264万
  • 项目类别:
DEVELOPMENTAL VIROLOGY RESEARCH--RESISTANCE TO ANTI-RETROVIRAL AGENTS
发育病毒学研究——抗逆转录病毒药物的耐药性
  • 批准号:
    2335293
  • 财政年份:
  • 资助金额:
    $ 264万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了